1-[2-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-5-methoxyphenyl]-1-propanone | 256443-71-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-5-methoxyphenyl]-1-propanone
• 英文别名: 1-[2-(4,4-dimethyl-5H-oxazol-2-yl)-5-methoxyphenyl]propan-1-one；1-[2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-5-methoxy-phenyl]-propan-1-one；1-[2-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-5-methoxyphenyl]propan-1-one
• CAS: 256443-71-7
• 化学式: C₁₅H₁₉NO₃
• 分子量: 261.321
• InChiKey: MYURDLOGGWLKNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  47.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[2-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-5-methoxyphenyl]-1-propanone 在 硫酸 作用下， 以 乙醇 、 水 为溶剂， 生成 4-ethyl-6-methoxy-2H-phthalazin-1-one
  参考文献：
  名称：

  Phthalazine derivatives phosphodiesterase 4 inhibitors

  摘要：

  本发明提供了一种从以下组中选择的化合物：1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-4-苯基-酞嗪；4-(3,5-二氯-吡啶-4-基甲基)-7-甲氧基-1H-酞嗪-2-羧酸甲酯；苄基-{3-{1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-酞嗪-5-基}-丙-2-炔基}-甲基-胺；1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-5-(5-吗啉-4-基-戊-1-炔基)-酞嗪二氢氯酸盐；3-{1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-酞嗪-5-基}-丙-2-炔-1-醇；1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-4-吗啉-4-基-酞嗪；1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-4-(1,2,4)三唑-1-基-酞嗪；其N→O衍生物；及其药用可接受盐。本发明还提供了一种药物组合物，包括与适宜载体混合的上述化合物的治疗有效量。

  公开号：

  US06329370B1
• 作为产物：
  描述：

  2-(4-甲氧基苯基)-4,4-二甲基-4,5-二氢-1,3-噁唑 、 乙烯 、 一氧化碳 在 十二羰基三钌 作用下， 以 甲苯 为溶剂， 160.0 ℃ 、3.6 kPa 条件下， 反应 20.0h， 以21%的产率得到1-[2-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-5-methoxyphenyl]-1-propanone
  参考文献：
  名称：

  Direct Carbonylation at a C−H Bond in the Benzene Ring of 2-Phenyloxazolines Catalyzed by Ru₃(CO)₁₂. Scope, Limitations, and Mechanistic Aspects

  摘要：

  The ruthenium-catalyzed carbonylation at a C-H bond in the benzene ring of a 2-phenyloxazoline is described. The reaction of 2-phenyloxazolines with CO and ethylene in toluene in the presence of a catalytic amount of Ru-3(CO)(12) resulted in propionylation at an ortho C-H bond in the benzene ring. The presence of the oxazoline ring on the benzene ring is essential for the carbonylation to proceed. Other heterocycles, such as oxazine, oxazole, and thiazoline rings, also served as acceptable directing groups as did the oxazoline ring. A wide functional group compatibility was observed. The site selectivity of the carbonylation was examined using meta-substituted phenyloxazolines. It was found that the carbonylation took place exclusively at the less-hindered C-H bond, irrespective of the nature of substituents, indicating that the site selectivity was determined by steric factors. The reaction was also applicable, not only to a benzene ring, but also to naphthyl and thiophenyl rings. Olefins such as propene and trimethylvinylsilane in place of ethylene could also be used in the carbonylation reaction, while other olefins, such as l-hexene, tert-butylethylene, vinylcyclohexane, isoprene, 1,5-hexadiene, cyclohexene, 1,5-cyclooctadiene, styrene, methyl acrylate, vinyl acetate, allyltrimethylsilane, and triethoxyvinylsilane did not afford the coupling products. An equilibrium between 2-phenyloxazolines, carbon monoxide, and olefins exists on one hand and the corresponding ketones on the other hand, and product composition is governed by the equilibrium thermodynamics of the system. The results of deuterium labeling experiments suggest that the catalysis involves a reversible C-H bond cleavage and that the rate-determining step is not the cleavage of a C-H bond. The results of kinetic study of the effects of CO pressure show that the reaction rate accelerates with decreasing CO pressure.

  DOI：

  10.1021/jo991660t

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021239885A1

  公开（公告）日：2021-12-02

  The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

  本发明涉及用于抑制NLRP3炎症体产生的新化合物，其中所述化合物由公式（I）定义，其中整数R1、R2和R3在描述中定义，且所述化合物可用作药物，例如用于治疗与NLRP3炎症体活性相关的一种疾病或失调。
• PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS
  申请人：ZAMBON GROUP S.p.A.

  公开号：EP1097142B1

  公开（公告）日：2004-10-13
• US6329370B1
  申请人：——

  公开号：US6329370B1

  公开（公告）日：2001-12-11
• US6492360B1
  申请人：——

  公开号：US6492360B1

  公开（公告）日：2002-12-10